Previous 10 | Next 10 |
2023-08-14 05:45:30 ET Summary Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could po...
2023-08-11 14:23:56 ET Summary Biogen focuses on neurological therapies, recently acquired Reata Pharmaceuticals, and shows mixed financial performance. Q2 2023 earnings reveal revenue decline, but strong liquidity; Alzheimer's treatments are key growth areas with notable developm...
2023-08-11 12:32:11 ET More on Sage Therapeutics Sage Therapeutics' Zuranolone Is A Lost Cause In Depression Market Sage Therapeutics: Zuranolone August Approval Likely, Opportunity Uncertain RBC Capital cuts Sage to sector perform, calls FDA decision "major setback"...
2023-08-10 09:00:00 ET Biogen (NASDAQ: BIIB) is an intriguing stock right now. Its business has struggled to generate growth in recent years, but some recent catalysts could turn things around. For starters, the company's Alzheimer's treatment, Leqembi, obtained approval from the Fo...
2023-08-09 17:58:16 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-08-09 08:30:00 ET Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news. After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it would acquire Reata Pharmaceuticals , a company that focuse...
2023-08-09 02:50:00 ET Summary While U.S. equities extended their rally, Morningstar’s Moat Index extended its year-to-date lead over the S&P 500 to nearly 800 basis points. U.S. Bancorp stood out as the top contributor. U.S. equity markets continued their rally in July...
2023-08-08 18:12:18 ET BofA Securities has upgraded Axsome Therapeutics ( NASDAQ: AXSM ) to neutral, citing an improved outlook for the company's drug Auvelity for major depressive disorder, or MDD. The investment bank said it was upgrading the stock primarily because Axsome's M...
2023-08-08 10:26:14 ET Shares of Eli Lilly ( NYSE: LLY ) hit an all-time high of $534.41 Tuesday morning, with the pharma briefly surpassing the $500B market cap mark. Q2 earnings beats combined with a bullish full-year outlook that prompted guidance boosts are responsible f...
2023-08-08 09:00:00 ET Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE) , a company that focuses on developing therapies for brain disorders. The stock plummeted by more than 53% after the company revealed that its blockbuster drug candidate, zuranolone, failed to win ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...